

Performance Improvement Continuing Medical Education (PI CME)
Performance Improvement Continuing Medical Education (PI CME) was introduced by the American Medical Association (AMA) in 2005. It is a process designed as a nationally standardized CME format to help healthcare professionals evaluate their current practice and improve their clinical processes and patient outcomes.
In this Performance Improvement CME activity, you will evaluate the performance in your own practice, develop and implement a plan for improving performance, and then re-evaluate your practice's performance on the selected quality measures. The program is a 3 stage process:
Stage A: Learning from Current Practice Performance Assessment (up to 5 hours of credit)
Stage B: Learning From the Application of Performance Improvement to Patient Care (up to 5 hours of credit)
Stage C: Learning From Evaluation of the Performance Improvement Effort (up to 5 hours of credit)
Bonus Credit: Physicians completing, in sequence, all three Stages (A through C) of a structured PI activity may receive an additional five (5) credits, for a maximum of twenty (20) credits per activity.
PI CME: Stroke Prevention In Atrial Fibrillation
In the United States an estimated 2.3 million individuals are currently affected by Atrial fibrillation (AF). It has been projected that by the year 2050 more than 5.6 million to nearly 16 million Americans will be affected by AF. Of particular concern is the association between AF, stroke and thromboembolism. AF has been associated with 15% of all strokes and with 36% of strokes in patients older than 80 years of age. This data suggests that the early identification and intervention in patients with AF at risk for stroke is crucial for improving outcomes.
20 AMA PRA Category 1 CME Credits™
>>Click here for additional details or to begin.
PI CME: Improving Outcomes in the Hospitalized Patient with Hyponatremia
This activity is developed in collaboration with the Society of Hospital Medicine. It is designed to help practitioners evaluate their clinical processes within hyponatremia care. Practitioners will learn to implement guideline-approved processes of care for hyponatremia patients, with special emphasis on risk stratification and identification of patients with t risk for the condition.
20 AMA PRA Category 1 CME Credits™
>>Click here for additional details or to begin.

|
 Online Programs >> Physician >> View All
Welcome to the CME-University Online Programs selection page. A complete listing of currently available online programs is provided below. To view program details associated with each listing click on the listed title of interest. To access course materials click the appropriate format available button (View PDF) (View Webcast), provided with each course detail.
To earn CE/CME credits you must review a course in its entirety and have successfully completed the course online post-exam. Online exams provide an immediate grade report along with a Letter of Completion. All Letters of Completion become a permanent part of your CME-University.com User Record and may be accessed anytime in the future for viewing and printing.
To refine the listing by a specific topic of interest, click a topic from the listing provided at the left side of this Online Programs section.

Achieving Treatment Success for Patients with Heart Failure Complicated by Hyponatremia
Effective Date: 10/15/2012
Expiration Date: 10/14/2014
Credits: 1.5
Tuition: Free
Faculty:
 Paul R. Hauptman, MD Professor of Internal Medicine, Division of Cardiology
Assistant Dean, Clinical and Translational Research
Saint Louis University Hospital, Saint Louis, MO
Paul J. Hauptman received his medical training at Cornell University Medical College and did his internal medicine residency at Brigham and Woman''s Hospital. He did his cardiology fellowship at Mount Sinai Hospital (NY) and at Harvard Medical School. He is Board certified in cardiovascular diseases. He is the Chairman of the Quality of Care Committee of the Heart Failure Society of America. Dr. Hauptman''s research interests include quality of life assessment and outcomes measurements in advanced heart failure.  Marvin A. Konstam, MD Professor, Tufts University School of Medicine
Director, Cardiovascular Center
Associate Professor of Medicine
Dr. Konstam is a Professor of Medicine (cardiology) and Professor of Radiology at Tufts University School of Medicine and Tufts-New England Medical Center (now Tufts Medical Center) continuously since 1981. He is Chief Physician Executive of The Cardiovascular Center, at Tufts Medical Center. He serves as the Chief of Cardiology and Director of Cardiovascular Development of New England Medical Center. Dr. Konstam is a cardiology specialist with vast experience in academic medicine and research. He served as the Chief of Cardiology at Tufts-NEMC from 1997 to 2007. In 2008, Dr. Konstam served as Senior Advisor for Cardiovascular Diseases at the National Heart, Lung, and Blood Institute, providing direction to the NHLBI's extramural cardiovascular research programs. His research has been published extensively in leading peer-reviewed medical journals and he lectured throughout the world on such topics as ventricular remodeling in heart failure, drug treatment and strategies for improving the quality of care. Dr. Konstam's principal clinical interest is heart failure and his principal areas of investigation are ventricular remodeling in heart failure, novel pharmaceutical and device treatment for heart failure, and strategies for improving quality of Cardiovascular care. He graduated from the College of Physicians and Surgeons, Columbia University, and did his post-graduate training at the Massachusetts General Hospital and Brigham and Womens' Hospital.  Linda J. Ordway, RN, MSN, ACNPc Nurse Practitioner, Cardiomyopathy Center
Cardiac Transplant and Ventricular Assist Device Program
Tufts Medical Center
Boston, Massachusetts
Ms Ordway is board certified as an Acute Care Nurse Practitioner and frequently lectures at Tufts Medical Center, as well as regional and national meetings. She has served on the Planning Committee for the American Heart Association Nurses Conference and has published many articles in peer-reviewed journals. In this program, she will highlight the scope and prevalence of hyponatremia in heart failure and describe a patient case with hyponatremia in the hospital setting.  John R Teerlink, FACC, FAHA, FESC, FRCP Professor of Medicine, University of California, San Francisco (UCSF)
Director, Heart Failure Program SFVAMC
Director, Clinical Echocardiography, SFVAMC
San Francisco VA Medical Center, San Francisco, CA
Dr. John R. Teerlink, F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P.(London) is Director of the Heart Failure Program and of the Clinical Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center in San Francisco, California. He graduated from Swarthmore College with Highest Honors in Comparative Religious Studies and Cellular Biology. After receiving his medical degree from Harvard Medical School, where he performed a year of research in the laboratory of Drs. Janice and Marc Pfeffer, he completed an internal medicine residency at the University of California San Francisco (UCSF). He continued his basic science training through a post-doctoral research fellowship at Hoffman-LaRoche in Basel, Switzerland with Drs. Martine and Jean-Paul Clozel. Dr. Teerlink completed his cardiovascular medicine fellowship and a Howard Hughes post-doctoral research fellowship at UCSF, subsequently joining the faculty, where he currently is a Professor of Medicine.
He is actively involved in the design and execution of many acute and chronic heart failure clinical trials, serving on endpoint, data safety monitoring, and steering committees for numerous international studies investigating a variety of new therapies, including tezosentan (RITZ program, VERITAS), levosimendan (REVIVE), nesiritide (ASCEND-HF), relaxin (Pre-RELAX-AHF, RELAX-AHF), rolofylline (PROTECT), omecamtiv mecarbil (CY1111, CY1121, ATOMIC-AHF), warfarin/ aspirin (WARCEF), and LCZ696 (PARADIGM-HF).
Dr. Teerlink has been an active member of the Heart Failure Society of America, serving on multiple committees including the Membership, Scientific Program, and Guideline Committees, and is a founding member of the American Association of Heart Failure Nurses. He has also served on the National Committee on Heart Failure and Transplantation of the American Heart Association. Dr. Teerlink completed a four-year term as a permanent member of the United States Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee, and currently serves as an ad hoc member of other FDA advisory committees and panels. He is a member of the joint FDA/ Duke University Standardized Data Collection for Cardiovascular Clinical Trials Initiative to develop standardized definitions for cardiovascular endpoints. He was an Associate Editor for the Journal of Cardiac Failure and is a clinical scholar presenting many lectures and publications, including a chapter on Acute Heart Failure in Braunwald's Heart Disease textbook.  Joseph G. Verbalis, MD Division Chief, Prof of Medicine, Endocrinology
Georgetown University Medical Center
Joseph G. Verbalis, MD is Professor of Medicine and Physiology and Chief of the Division on Endocrinology and Metabolism at Georgetown University. He was previously a faculty member at the University of Pittsburgh from 1980-1995 until he was recruited to GU. From 2004 to 2007 he served as interim chair of the Department of Medicine, and relinquished this position to direct Georgetown's CTSA effort. He was one of the founding PIs of the GU GCRC in 1999, served as Chair of the GAC from 1999 to 2002, and has been the Program Director of the GCRC since 2002. He has been continuously funded as a PI on NIH research grants since 1988, and is currently the PI of two NIH R01s focusing on mechanistic studies of kidney and bone complications of hyponatremia, and the GU/MedStar CTSA Planning grant, and is a co-PI of an R01 studying hormonal effects on cognition in post-menopausal women. In 2007 he was the awarded the Berthold Medal by the German Endocrine Society for outstanding scientific achievement in endocrinology by individuals who have excelled in combining both basic and clinical research. He has mentored many fellows and junior faculty members through directorship of the endocrinology fellowship training programs at both the University of Pittsburgh and GU, and is a member of the training faculty of the GU T32 Interdisciplinary Program in Neuroscience.
Format:
Webcast
Description: Hyponatremia is very difficult to treat in patients with heart failure, and improved treatment strategies represent an urgent clinical need. Recently, vasopressin has emerged as a therapeutic target in the management of hyponatremia. Vasopressin is a central modulator in hyponatremia, underscoring the importance of antagonizing vasopressin at its receptors in patients with hyponatremia and underlying heart failure. Guidelines for the treatment of hyponatremia have been published by several professional associations. The varying recommendations and emerging data on treatment options create challenges for practitioners caring for patients with hyponatremia. Recognizing the possible consequences of unmanaged hyponatremia in heart failure patients and implementing appropriate treatment strategies are critical steps toward improving outcomes in patients with hyponatremia.
IMPORTANT PROGRAM VIEWING INFORMATION: To participate in this program you must be registered and logged in to this website.
|